

## PRIOR AUTHORIZATION REQUEST FORM EOC ID: IDHIFA (enasidenib)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

D.C. of No.	Prescriber Name:	
Patient Name:	Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. Please provide ICD code(s) for diagnosis		
Q2. What diagnosis is this drug being prescribed for?		
<ul><li>☐ Relapsed or refractory acute myeloid leukemia (AML)</li><li>☐ Other</li></ul>		
Q3. If you selected "other" in question 2, please provid higher recommendation per NCCN compendia or guide		ent with a category 2A or
Q4. Is prescribing physician a hematology or oncology sp	ecialist?	
☐ Yes ☐ No		
Q5. Is the patient 18 years of age or older?		
☐ Yes ☐ No		
Q6. If indication is AML, does the patient have an isocitra approved test?	te dehydrogenase-2 (IDH2) mutatio	n as detected by an FDA-
☐ Yes ☐ No		



## PRIOR AUTHORIZATION REQUEST FORM EOC ID: IDHIFA (enasidenib)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.		
	Prescriber Name:	
Patient Name:	Supervising Physician:	
Q7. Additional Comments		
Prescriber Signature	Date	
	signing above, I certify that applying the standard review timeframe may llee or the enrollee's ability to regain maximum function	
	medical necessity denial. Requesting providers may speak to the SWHP medical e an opportunity to help impact the decision on a request before coverage has beer	
entity named above. The authorized recipient of this information is pro-	g to the sender that is legally privileged. This information is intended only for the use of the individual or oblibited from disclosing this information to any other party. If you are not the intended recipient, you are en in reference to the contents of this document is strictly prohibited. If you have received this telecopy in if this document	